

Astrazeneca-Oxford Vaccine- Could Be The Game Changer For Global Immunization

Ayushi Goel*

Department of Computer Science, B.tech, Meerut Institute of Engineering and Technology, Meerut

INTRODUCTION

2020 has been a troublesome year for all, however has seen a total of 58 vaccines few developed and a few under clinical trials against acute syndrome of corona virus 2. Some vaccines reportedly have shown 90% efficiency against Covid-19 in clinical trials. This outstanding accomplishment is much needed excellent news as Covid-19 cases are currently at their daily highest level globally.

WHO has approved 2 vaccines of AstraZeneca-Oxford COVID-19 vaccine allowing all the shots rolled out globally? These vaccines are prepared by AstraZeneca-SKBio (Republic of Korea) and Serum Institute of India (SII). AstraZeneca informed Reuters that its Covid-19 vaccine is potentially effective against the new Corona virus variant with studies fully analyze the impact of mutation. The company has already submitted fully data package to British medicine regulators.

The vaccine aims to be a non-profit vaccine which makes it globally attractive and pushes it closer to its goal of worldwide supply for low-middle income countries. New vaccine results are reported within the Lancet: investigators of four randomized controlled trials conducted with the Britain's, African countries and Brazil report pooled results of an interim analysis of safety and efficient against Covid-19 of the Oxford AstraZeneca, Ponzid animal virus vectored vaccine in adult aged 18 years and older. It has all the approval by British and Indian Government allowing distribution to some of the world's poor countries to begin, giving the priority to health workers who are under high risk of expose and older people (65 years and above). It is the second corona virus injection which has been cleared by United Kingdom for emergency use after the one from Pfizer Inc. and Biotech which was authorized in early December.

The dose is given intramuscularly under the regime of 2 doses (0.5ml each) having an interval of 8-12 weeks. Though the production is limited but cheaper and easier to distribute. Thus, the vaccine could be the solution for the global pandemic.

REFERENCES

1. Zimmer C, Corum J, Wee S. Coronavirus vaccine tracker. New York Times. 2020
2. Center for Systems Science and Engineering at Johns Hopkins University COVID-19 dashboard. Johns Hopkins University of Medicine coronavirus resource center.
3. Voysey M, Clemens SAC, Madhi SA. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020 doi: 10.1016/S0140-6736(20)32661-1.
4. Gavi. the Vaccine Alliance New collaboration makes further 100 million doses of COVID-19 vaccine available to low- and middle-income countries. Sept 29, 2020.
5. Amnesty International COVID-19: Oxford/AstraZeneca vaccine a boost for global access, but huge inequality remains. Nov 23, 2020.
6. Ramasamy MN, Minassian AM, Ewer KJ. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2020 doi: 10.1016/S0140-6736(20)32466-1. published online Nov 19.
7. McCarthy N. The cost per jab of Covid-19 vaccine candidates. Statista. Dec 1, 2020
8. Privor-Dumm LA, Poland GA, Barratt J. A global agenda for older adult immunization in the COVID-19 era: a roadmap for action. Vaccine. 2020 doi: 10.1016/j.vaccine.2020.06.082. published online July 3
9. WHO WHO Concept for fair access and equitable allocation of COVID-19 health products. Sept 9, 2020.

*Correspondence to: Ayushi Goel, Department of Computer Science, B.tech, Meerut Institute of Engineering and Technology, Meerut; Tel No: 9756694451; E-Mail: ayushi.aashi25@gmail.com

Received Date: March 15, 2021; Accepted Date: September 08, 2021; Published Date: September 18, 2021

Citation: Goel A (2021) Astrazeneca-Oxford Vaccine- Could Be The Game Changer For Global Immunization. J Membra Sci Technol; 11:257.

Copyright: © 2021 Goel A. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.